The same group also found glucagon-like peptide 1 receptor agonist (GLP-1 RA) use in diabetic HF patients was associated with a 3.7-fold increase in CRT response at 1-year follow-up (HR 3.707; 95% CI 1.226–14.570; p = 0.026) [128], which is particularly relevant given recent interest in this drug class [129,130], and the growing prevalence of diabetes among HF patients [5]. Here, GLP1R is linked to diabetes mellitus.